Description
Retatrutide (LY3437943) is an innovative peptide under development by Eli Lilly for therapy in overweight, obesity, and type 2 diabetes (T2D). Functioning as a triple-agonist, the peptide has the ability to simultaneously engage with three key receptors: glucagon (GCGR), as well as the receptors for the incretin hormones GLP-1 (GLP-1R) and GIP (GIPR). Data from phase 1b and phase 2 trials reveal that retatrutide is notably effective in promoting weight loss and enhancing glycemic control in patients with type 2 diabetes (T2D). Furthermore, a substudy within one of the phase 2 trials highlights its effectiveness in reducing liver fat in individuals with obesity and metabolic-dysfunction-associated steatohepatitis (MASH).
Retatrutide Dose: Initiated at 2mg/weekly for the first four weeks of the study period, followed by an increase to 4mg/weekly in weeks 5-8, 8mg/weekly in weeks 9-12, 12mg/weekly in weeks 13 and beyond.
Frequency: Once weekly; subcutaneously.
Cycle Duration: up to 48 weeks.
Dosage should never exceed 12mg/weekly. Missed doses should be administered within 5 days or skipped, and consequent doses should taken according to the initial schedule
